Hepatitis C Virus
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS FORM STRATEGIC ALLIANCE TO DEVELOP RNAi HEPATITIS C DRUG
Published in Hepatitis Weekly, July 9th, 2007
Oncolys BioPharma, Inc. (Tokyo, Japan) and Tacere Therapeutics, Inc. (San Jose, CA, USA) announced today that they have entered into a strategic alliance to develop TT-033, Tacere's lead clinical program. Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033, a novel RNA interference (RNAi) based product for the treatment of hepatitis C (HCV), which Oncolys will market as OBP-701. Further, Oncolys has made an equity investment in Tacere of an undisclosed amount.
"We are extremely excited about forming a collaborative relationship with Tacere, one of the pioneers in RNAi, as OBP-701/TT-033 greatly expands and perfectly matches...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-07-09)
More Articles from Hepatitis Weekly
- HIV/AIDS
Needle-stick injuries are common but unreported by surgeons in training - Hepatitis
Genesis Dental Technologies, LLC Launches New Web Site Featuring the AquaSept Independent Water Delivery System to Prevent Disease Transmission in Dental Water - Hepatitis B Virus
Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint - Hepatitis C Virus
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of the NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection - Hepatitis C Virus
Energex System's Experimental Non-Pharmacological Treatment Exceeds Expectations in Reducing Liver Inflammation in Refractory Hepatitis C Patients - Hepatitis C Virus
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
